Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2005-05-17
2005-05-17
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S218100, C424S277100, C435S235100, C435S320100, C435S325000
Reexamination Certificate
active
06893643
ABSTRACT:
The present invention provides recombinant yellow fever viruses (YFV), particularly live attenuated recombinant YFV, which comprise exogenous (i.e., non-YFV) nucleotide sequences which encode exogenous (i.e., non-YFV) amino acid sequences. These recombinant YFV viruses comprise an exogenous nucleic acid. Infection of a host cell with a recombinant YFV provides for expression of the exogenous nucleic acid in a host cell and production of an antigenic polypeptide encoded by the exogenous nucleic acid. Such recombinant YFV are useful in eliciting an immune response to the exogenous polypeptide.
REFERENCES:
patent: 5965124 (1999-10-01), Feinberg et al.
patent: 6184024 (2001-02-01), Lai et al.
patent: 6589531 (2003-07-01), Andino-Pavlovsky et al.
patent: WO 9306214 (1993-04-01), None
patent: WO 9700322 (1997-01-01), None
patent: WO 9837911 (1998-09-01), None
patent: WO 9928487 (1999-06-01), None
Galler et al., “The Yellow Fever 17D Vaccine Virus: Molecular Basis of Viral Attenuation and its use as Expression Vector”, Brazilian Journal of Medical and Biological Research 30(2): 157-168, 1997.
Monath et al., “Recombinant Live, Attenuated Vaccine (ChermiVax™Incorporating the Genes of Japanese Encephalitis (SA 14-14-2) Virus and the Capsid and Nonstructural Genes of Yellow Fever (17-D) Virus . . . ” Vaccine 17:1869-1882, 1999.
Alexander et al. (1994) “Strategies for Inducing and Evaluating Mucosal Immunity: Dicistronic Polioviruses as Expression Vectors for Foreign Genes.”AIDS Research and Human Retroviruses,vol. 10(2):S57-S60.
Amberger et al (1994) “Characterization of a Membrane-bound Metalloendoprotease of Rat C6 Glioblastoma Cells.” vol. 54:4017-4025.
Andino et al. (1994) “Engineering Poliovirus as a Vaccine Vector for the Expression of a Diverse Antigens.”Science,vol. 265:1448-1451.
Bohm et al. (1998) “T Cell-Mediated, IFN-γ-Facilitated Rejection of Murine B16 melanomas.”The Journal of Immunology,vol. 161(2):897-908.
Boon (1993) “Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy.”Int. J. Cancer,vol. 54:177-180.
Boon et al. (1992) “Identification of Tumour Rejection Antigens Recognized by Lymphocytes.”Cancer Surveys,vol. 13:23-37.
Burke et al. (1991) “Antigen Chimeras of Poliovirus.”Prog. Med. Virol.,vol. 38:56-68.
Carroll et al. (1997) “Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model.”Vaccine,vol. 15(4):387-394.
Chambers et al. (1991) “Processing of the Yellow Fever Virus Nonstructural Polyprotein: a Catalytically Active NS3 Proteinase Domain and NS2B Are Required for Cleavages at Dibasic Sites.”Journal of Virology,vol. 65(11):6042-6050.
Chambers et al. (1999) “Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties.”Journal of Virology,vol. 73(4):3095-3101.
Chambers et al. (1990) “Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein.”Proc. Natl. Acad. Sci USA,vol. 87:8898-8902.
Chen et al. (1996) “Therapeutic Antitumor Response After Immunization with a Recombinant Adenovirus Encoding a Model Tumor-Associated Antigen.”The Journal of Immunology,vol. 156(1):224-231.
de Zoelen et al. (1998) “Resistance to Melanoma in Mice Immunized with Semiallogeneic Fibroblasts Transfected with DNA from Mouse Melanoma Cells.”The Journal of Immunology,vol. 160(6):2915-2922.
Dranoff et al. (1993) “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrohage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.”Proc. Natl. Acad. Sci. USA,vol. 90:3539-3543.
Dranoff et al. (1997) “A Phase I Study of Vaccination with Autologous, Irradiated Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor.”Human Gene Therapy,vol. 7:111-123.
Ellem et al. (1997) “A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.”Cancer Immunol Immunother.,vol. 44:10-20.
Falo et al. (1995) “Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity.”Nature Medicine,vol. 1(7):649-653.
Guirakhoo et al. (1999) “Immunogenicity, genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese Encephalitis.”Virology,vol. 257:363-372.
Kawakami et al. (1994) “Identification of a human melanoma antigen recoginzed by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.”Proc. Natl. Acad. Sci. USA,vol. 91:6458-6462.
Kawakami et al. (1994) “Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes.”The Journal of Experimental Medicine,vol. 180:347-352.
Kawakami et al. (1994) “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.”Proc. Natl. Acad. Sci. USA,vol. 91:3515-3519.
Khromykh et al. (1997) “Subgenomic Replicons of the Flavivirus Kunjin: Construction and applications.”Journal of Virology,vol. 71(2):1497-1505.
Lu et al. (1995) “Construction and Genetic Analysis of Dicistronic Polioviruses Containing Open Reading Frames for Epitopes of Human Immunodeficiency Virus Type 1 gp120.”Journal of Virology,vol. 69(8):4797-4806.
Mandl et al. (1998) “Poliovirus vaccine vectors elicit antigen-specific cytotoxic t cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen.”Proc. Natl. Acad. Sci. USA,vol. 95:8216-8221.
Monath (1991) “Yellow Fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future.”Am. J. Trop. Med. Hyg.,vol. 45(1):1-43.
Monath et al. (1993) “Should Yellow Fever Vaccine be Included in the Expanded Program of Immunization in Africa? A Cost-Effectiveness Analysis for Nigeria.”Am. J. Trop. Med. Hyg.,vol. 48(2):274-299.
Monath et al. (1999) “Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA144-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, Immunogenic and protective in non-human primates.”Vaccine,vol. 17:1869-1882.
Monath (1990) Flaviviruses. In Virology, G.N. Fields, and D.M. Knipe, eds. Raven Press, Ltd., New York. pp. 763-814.
Meuller et al. (1998) “Expression of Foreign Proteins by Poliovirus Polyprotein Fusion: Analysis of genetic Stability Reveals Rapid deletions and Formation of Cardioviruslike Open Reading Frames.”Journal of Virology,vol. 72(1):20-31.
Overwijk et al. (1999) “Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes.”Proc. Natl. Acad. Sci. USA,vol. 96:2982-2987.
Poland et al. (1981) “Persistence of neutralizing antibody 30-35 years after immunization with 17D Yellow fever vaccine.”Bulletin of the World Health Organization,vol. 59(6):895-900.
Reinhardt et al. (1998) “Development of Viremia and Humoral and Cellular Parameters of Immune Activation After Vaccination With Yellow Fever Virus Strain 17D: A Model of Human Flavivirus Infection.”Journal of Medical virology,vol. 56:159-167.
Restifo et al. (1996) “The new vaccines; building viruses that elicit antitumor immun
Andino-Pavlovsky Raul
McAllister-Moreno Andres
Borden Paula A.
Bozicevic Field & Francis LLP
Mosher Mary E.
LandOfFree
Recombinant yellow fever virus and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant yellow fever virus and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant yellow fever virus and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3450037